| Literature DB >> 30428842 |
Xu Huang1,2, Xiangjun Cheng1,2, Pengfei Sun1,2, Chenjie Tang1,2, Fang Ni1,2, Genyan Liu3,4.
Abstract
BACKGROUND: The emergence of carbapenem-resistant Klebsiella pneumoniae (CR-KP) has become a significant problem worldwide and also being a major threat to children and newborns. Here we report an outbreak of NDM-1-producing K. pneumoniae in a neonatal unit.Entities:
Keywords: Multidrug-Resistant, carbapenem-resistant Klebsiella pneumoniae; Neonate; Outbreak; bla NDM-1
Mesh:
Substances:
Year: 2018 PMID: 30428842 PMCID: PMC6234558 DOI: 10.1186/s12866-018-1334-1
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Clinical profiles of the six NDM-1-positive K. pneumoniae isolates
| Case | Sex | Pregnancy duration (wk) | Sample type | Type of infections | Antimicrobial therapy | PFGE type | ST type | NDM-coding plasmids (Kb) |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 32 | Blood | Neonatal sepsis, neonatal respiratory distress syndrome | meropenema | A | 234 | none |
| 2 | F | 31 | Blood | Neonatal sepsis, neonatal respiratory distress syndrome | meropenem | A | 234 | none |
| 3 | M | 26 | Sputum | Neonatal respiratory distress syndrome | imipenemb | B | 1412 | 50 |
| 4 | M | 30 | Blood | Neonatal sepsis, neonatal respiratory distress syndrome | meropenem | B | 1412 | 50 |
| 5 | M | 35 | Blood | Neonatal sepsis, neonatal pneumonia | meropenem | B | 1412 | 50 |
| 6 | M | 29 | Blood | Neonatal sepsis | meropenem | B | 1412 | 50 |
ameropenem 0.5 g IVD,qd; b imipenem 1.0 IVD qd;
Antimicrobial susceptibilities of the six NDM-1-positive K. pneumoniae isolates
| Isolate No. | Resistance mechanisms | MIC(mg/liter) ofa | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCF | IPM | CAZ | MEM | TZP | PB | FEP | AM | PIP | LE | TG | ATM | ||
| KP1 | NDM-1, CTX-M-14, SHV-27,qnrB4 | > 128 | 64 | > 128 | 64 | > 128 | 0.5 | 64 | 0.125 | > 128 | < 0.125 | 0.125 | 4 |
| KP2 | NDM-1, CTX-M-14, SHV-27,qnrB4 | > 128 | 64 | > 128 | 64 | > 128 | 0.5 | 64 | 0.125 | > 128 | < 0.125 | < 0.125 | 4 |
| KP3 | NDM-1, SHV-148 | > 128 | 32 | > 128 | > 128 | > 128 | 2 | > 128 | 0.25 | > 128 | < 0.125 | 0.25 | 4 |
| KP4 | NDM-1, SHV-148 | > 128 | 32 | > 128 | > 128 | > 128 | 1 | > 128 | 0.25 | > 128 | < 0.125 | < 0.125 | 4 |
| KP5 | NDM-1, SHV-148 | > 128 | 32 | > 128 | > 128 | > 128 | 1 | 64 | 1 | > 128 | < 0.125 | < 0.125 | 8 |
| KP6 | NDM-1, SHV-148 | > 128 | 32 | > 128 | 32 | > 128 | 1 | 32 | 1 | > 128 | < 0.125 | < 0.125 | 0.125 |
| J53–3 | NDM-1 | > 128 | 16 | > 128 | 32 | > 128 | 2 | 128 | 8 | > 128 | < 0.125 | < 0.125 | 0.25 |
| J53–4 | NDM-1 | > 128 | 32 | > 128 | 32 | > 128 | 2 | 64 | 4 | > 128 | < 0.125 | < 0.125 | 0.25 |
| J53–5 | NDM-1 | > 128 | 8 | > 128 | 8 | > 128 | 2 | 32 | 2 | > 128 | < 0.125 | < 0.125 | < 0.125 |
| J53–6 | NDM-1 | > 128 | 8 | > 128 | 8 | > 128 | 2 | 32 | 4 | > 128 | < 0.125 | < 0.125 | 0.25 |
aSCF, sulbactam/cefoperazone; IPM, imipenem; CAZ, ceftazidime; MEM, meropenem; TZP, piperacillin /tazobactam; PB, polymixin B; FEP, cefepime; AM, amikacin; PIP, piperacillin; LE, levofloxacin; TG, tigecycline; ATM, aztreonam
Fig. 1Pulsed-field gel electrophoresis analysis of isolated NDM-1- producing K. pneumoniae strains. A, Pulsed-field gel electrophoresis fingerprint of the isolates; B, Molecular epidemiology investigation of the isolates; KP1 to KP6: patients; KP7: incubator surface; KP 8: head circumference tape; KP 9: blood machine surface; KP 10: healthcare worker; lane M: marker (Salmonella H9812)
Fig. 2blaNDM-1-carrying plasmid analysis. A S1 nuclease pulsed-field gel electrophoresis (PFGE); B Southern hybridization using a blaNDM-1-specific probe; Lane M: marker (Salmonella H9812); KP1 to KP6: clinical isolates